LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 04/19/22

(TheNewswire) HYPER-H21-4 will evaluate DehydraTECH TM -CBD for reducing blood pressure together with other potential clinical benefits This s tudy is designed to enhance Lexaria’s probabilities of success with its ...

Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration KELOWNA, BC / ACCESSWIRE / April 14, 2022 / Lexaria Bioscience Corp. (N...

(TheNewswire) Data from this human study, together with the findings from Lexaria’s other previously announced successful studies, intended to support the Company’s plans to seek approvals by the U.S. Food and Drug Administration K...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“...

Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States suc h as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...

(TheNewswire) Kelowna, British Columbia – TheNewswire - April 11, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, ann...

Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing. KELOWNA, BC / ACCESSWIRE / March 15, 2022 / Lexaria Bioscien...

Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted a new patent entitled ...

DehydraTECH TM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings in...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today provided an annual letter from CEO Chris Bunka and a thorough strategic update to all stakeholders. In the update, Bunka described Lexaria’s key area of focus to improve the company’...